Harbour BioMed

Harbour BioMed was established in 2016 with an initial financing of US $50 million from Advantech Capital, Legend Capital and the Harbour BioMed founding team. The company is headquartered with R&D operations in Shanghai, business operations in Cambridge, MA, and antibody platform innovation operations in Rotterdam, The Netherlands. The Company's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve.

Harbour BioMed has 272 total employees. The trailing twelve month revenue for Harbour BioMed is $158M. The company operates as a public company and maintains global R&D centers in the USA, Europe, and China to identify and leverage local innovation for global development. 2025 financial highlights show total revenue reached approximately US$158 million, representing an increase of 314.6% year over year, primarily driven by long-term strategic collaborations with multinational pharmaceutical companies, global licensing agreements, and robust revenue growth fueled by the strong performance of Nona Biosciences.

Recent Leadership News

In April 2026, Harbour BioMed announced the appointment of Dr. Adam Zong as President. Dr. Zong is based in Shanghai and reports directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer. In this role, Dr. Zong is responsible for strengthening the Company's internal product pipeline, advancing the strategic development of its overall portfolio, and leading asset strategy and partnership initiatives.